PLoS ONE (Jan 2017)

A Comparison of Three Quantitative Methods to Estimate G6PD Activity in the Chittagong Hill Tracts, Bangladesh.

  • Benedikt Ley,
  • Mohammad Shafiul Alam,
  • James J O'Donnell,
  • Mohammad Sharif Hossain,
  • Mohammad Golam Kibria,
  • Nusrat Jahan,
  • Wasif A Khan,
  • Kamala Thriemer,
  • Mark D Chatfield,
  • Ric N Price,
  • Jack S Richards

DOI
https://doi.org/10.1371/journal.pone.0169930
Journal volume & issue
Vol. 12, no. 1
p. e0169930

Abstract

Read online

BackgroundGlucose-6-phosphate-dehydrogenase-deficiency (G6PDd) is a major risk factor for primaquine-induced haemolysis. There is a need for improved point-of-care and laboratory-based G6PD diagnostics to unsure safe use of primaquine.MethodsG6PD activities of participants in a cross-sectional survey in Bangladesh were assessed using two novel quantitative assays, the modified WST-8 test and the CareStart™ G6PD Biosensor (Access Bio), The results were compared with a gold standard UV spectrophotometry assay (Randox). The handheld CareStart™ Hb instrument (Access Bio) is designed to be a companion instrument to the CareStart™ G6PD biosensor, and its performance was compared to the well-validated HemoCue™ method. All quantitative G6PD results were normalized with the HemoCue™ result.ResultsA total of 1002 individuals were enrolled. The adjusted male median (AMM) derived by spectrophotometry was 7.03 U/g Hb (interquartile range (IQR): 5.38-8.69), by WST-8 was 7.03 U/g Hb (IQR: 5.22-8.16) and by Biosensor was 8.61 U/g Hb (IQR: 6.71-10.08). The AMM between spectrophotometry and WST-8 did not differ (p = 1.0) but differed significantly between spectrophotometry and Biosensor (p0.05). Sensitivity and specificity for detecting G6PD activity ConclusionWST-8 and the CareStart™ G6PD Biosensor represent advances in G6PD diagnostics in resource poor settings, but will require further development before clinical deployment. The CareStart™ Hb instrument produced a precise measure of haemoglobin concentration.